SOURCE: Torbay Holdings, Inc.

March 29, 2007 11:50 ET

Torbay Holdings, Inc.: New Research Suggests the Potential for an RSI Blood Test

LONG BEACH, NY -- (MARKET WIRE) -- March 29, 2007 -- Torbay Holdings, Inc. (OTCBB: TRBY) today reports on new research that suggests the possibility in the future that a simple blood test could be used to indicate a diagnosis of RSI due to repetitive motion. The findings are contained within a paper called:

"Inflammatory biomarkers increase with severity of upper-extremity overuse disorders." Stephen J. Carp et al. Published in: Clinical Science (2007) 112, 305-314

This research follows previous studies that noted cytokine (biomarkers) increase in rats following several weeks of induced repetitive activity. In this study on human subjects these biomarkers were seen to have a dose dependent relationship, which means that an increase in the levels of the biomarkers correlated with the degree of overuse. Therefore RSI severity may correlate with an increase in these biomarkers. Subjects with multiple injury sites had proportionately higher levels of biomarkers in their bloodstream.

A Torbay synopsis of the findings:

1. Early onset RSIs due to overuse and with inflammation have a direct positive correlation with serum [blood] levels of key markers.

2. Increased levels correlate with local signs of pain, tenderness, peripheral nerve irritation, weakness and limited motion, as well as multiple sites.

3. The results of the study indicate that the inflammatory markers show an underlying "low-grade" inflammation process is induced by overuse.

4. There are other low-grade chronic conditions that give responses at the levels detected, which need to be eliminated as a diagnosis. Once eliminated then a presence of these markers indicates RSI as a likely diagnosis.

This research suggests the future possibility for a simple blood test as part of a clinical diagnostic for RSI. In that event claims for repetitive injury, in all workers and not just computer workers, may have greater clinical justification.

In concert with the recent Mayo Clinic study that suggests that carpal tunnel syndrome is as a result of injury due to finger activity, we believe that the potential for a blood test in the future will provide for a clearer understanding of the role that input devices may have in the development of overuse injuries in computer workers. This may require greater attention on the part of employers and workers compensation systems to provide input device products that are better designed for the physiology of the worker and not just products that focus upon the work.

In such an event, product design that may better respect human physiology, such as Torbay's Anti-Fatigue™ patented designs, will likely receive the recognition they deserve for reducing the physiological load placed upon computer user's hands. Grip and palm down mousing consumes greater physiological resource than working in a grip-less untwisted wrist posture. In today's energy conservation conscious world the principal of fuel efficiency is equally applicable to the consumption of human energy and Torbay improves "mouse mileage" by making a more fuel efficient mouse!

Link to Biomarker Study PR: http://develop.temple.edu/temple_times/february07/repetitivemotion.html

Designer Appliances, Inc. is leading the way in the development of Anti.Fatigue™ tools and technologies to manage the impact that fatigue is now understood to have upon computer users. Anti.Fatigue™ design conforms to Universal Design criteria so produces products that are more "Accessible and Assistive" to all, including persons with dexterity impairment or disability. We are all capable of fatigue.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this release that are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause results to differ materially from those expressed in the forward-looking statements, including but not limited to, certain delays and risks detailed from time to time in the company's filings with the Securities and Exchange Commission.

Contact Information